Andrii Yalanskyi Immunotherapy developer Barinthus Biotherapeutics ( NASDAQ: BRNS ) has decided to reduce its workforce by roughly 25% as part of a restructuring drive to revamp its pipeline. According to the plan, the company will prioritize its experimental therapies, VTP-300 and VTP-1000, targeted at chronic hepatitis B (CHB) and celiac disease, respectively, instead of its cancer therapy, VTP-850. In a press release late Wednesday, Barinthus ( BRNS ) said that the decision to give VTP-300 and VTP-1000 priority follows encouraging clinical and preclinical data the duo has already generated.
However, Barinthus ( BRNS ) said an ongoing Phase 1 trial for VTP-850 in prostate cancer will be completed. The restructuring program is expected to extend the company's cash runway into Q2 2026. "In line with our pipeline prioritization, we have made the difficult decision to reduce our workforce.
I would like to thank our talented employees for their contributions to the company's achievements," said CEO Bill Enright. More on Barinthus Biotherapeutics Seeking Alpha’s Quant Rating on Barinthus Biotherapeutics Historical earnings data for Barinthus Biotherapeutics Financial information for Barinthus Biotherapeutics.
